IDEXX Laboratories (NASDAQ:IDXX) Price Target Lowered to $675.00 at Stifel Nicolaus

IDEXX Laboratories (NASDAQ:IDXX) had its price target decreased by Stifel Nicolaus from $775.00 to $675.00 in a report issued on Tuesday,Benzinga reports. Stifel Nicolaus currently has a buy rating on the stock.

Several other equities analysts also recently issued reports on IDXX. Piper Sandler decreased their price objective on shares of IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating for the company in a research note on Monday, February 9th. Weiss Ratings downgraded IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a report on Thursday, January 29th. UBS Group decreased their target price on IDEXX Laboratories from $750.00 to $730.00 and set a “neutral” rating for the company in a research report on Tuesday, February 3rd. BTIG Research dropped their price target on IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating on the stock in a research note on Tuesday, February 3rd. Finally, Wall Street Zen lowered IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 28th. Seven analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $772.22.

IDEXX Laboratories Price Performance

IDXX stock opened at $561.89 on Tuesday. The business has a 50 day moving average price of $625.67 and a 200 day moving average price of $660.90. The company has a quick ratio of 0.90, a current ratio of 1.23 and a debt-to-equity ratio of 0.23. The stock has a market cap of $44.63 billion, a price-to-earnings ratio of 42.99, a PEG ratio of 3.38 and a beta of 1.66. IDEXX Laboratories has a fifty-two week low of $356.14 and a fifty-two week high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings results on Monday, February 2nd. The company reported $3.08 EPS for the quarter, beating the consensus estimate of $2.93 by $0.15. IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. The company had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.07 billion. During the same period in the prior year, the firm posted $2.53 earnings per share. The firm’s revenue was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. Equities research analysts anticipate that IDEXX Laboratories will post 11.93 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, EVP George Fennell sold 11,345 shares of the company’s stock in a transaction dated Tuesday, February 10th. The shares were sold at an average price of $646.72, for a total value of $7,337,038.40. Following the completion of the sale, the executive vice president directly owned 9,823 shares of the company’s stock, valued at approximately $6,352,730.56. This represents a 53.60% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Sophie V. Vandebroek sold 1,464 shares of the firm’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $628.62, for a total value of $920,299.68. Following the transaction, the director directly owned 648 shares in the company, valued at approximately $407,345.76. This represents a 69.32% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 45,957 shares of company stock valued at $29,862,109 in the last quarter. Corporate insiders own 0.98% of the company’s stock.

Institutional Trading of IDEXX Laboratories

A number of hedge funds have recently added to or reduced their stakes in the stock. SHP Wealth Management purchased a new position in IDEXX Laboratories in the 4th quarter valued at $26,000. Virtus Advisers LLC purchased a new stake in shares of IDEXX Laboratories in the third quarter valued at about $26,000. Park Place Capital Corp acquired a new position in shares of IDEXX Laboratories during the fourth quarter worth about $29,000. J.Safra Asset Management Corp purchased a new position in IDEXX Laboratories during the third quarter worth about $31,000. Finally, Armstrong Advisory Group Inc. lifted its position in IDEXX Laboratories by 55.9% in the third quarter. Armstrong Advisory Group Inc. now owns 53 shares of the company’s stock valued at $34,000 after purchasing an additional 19 shares during the period. 87.84% of the stock is owned by institutional investors and hedge funds.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.